Voyager Therapeutics is trading at $2.06, down 5.71%, with no confirmed catalyst identified.
- Voyager announced Robin Swartz as president, effective October 20; she is expected to succeed CEO Alfred Sandrock in Q1 2027, following anticipated VY1706 safety data.
- Available reporting does not confirm the announcement caused the decline.
- Biotech sector context is positive: XBI is up 2.10%, so it does not explain the drop.